FMC (FMC) investor relations material

Strategic partnerships and portfolio transformation

• Signed a $200 million licensing deal with Corteva for a dual-mode AI molecule, supporting debt reduction and expanding market reach, with first sales expected in 2028.

• Retains manufacturing and global rights outside corn and soybean in the Americas, while both parties can sell their own formulations.

• Ongoing asset sales, including the India business and a flotation chemical business, have brought debt reduction efforts to nearly $500 million, with a real estate deal expected to push this further.

• Strategic review process is ongoing, with an aim to conclude by the Q2 earnings call in July.

Market outlook and commercial strategy

• Confirms Q2 guidance and maintains full-year targets, citing strong order book and improved commercial execution, especially in Latin America.

• Order book for the second half is at the upper end of historical ranges, more than double last year, driven by a shift to direct sales to large farms and co-ops.

• Pricing pressure persists, especially for Rynaxypyr, but there are early signs of stabilization in some markets, though caution remains.

Product innovation and future growth

• Four new molecules, including rimisoxafen, are set to launch between 2025 and 2028, each with $500–$700 million sales potential; a fifth fungicide is expected by 2030.

• Portfolio is shifting from insecticide-heavy to a more balanced mix of herbicides, fungicides, and insecticides, aligning with market needs and increasing predictability.

• Isoflex, recently launched in Europe, is expected to surpass previous flagship products in volume and generate over $300 million in Europe within a few years.

• Fluindapyr and Isoflex together are projected to contribute $300–$400 million in revenue this year, with further upside possible from emergency use exemptions.